4 236

Cited 10 times in

Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy

DC FieldValueLanguage
dc.contributor.author김상진-
dc.contributor.author김태훈-
dc.contributor.author박철환-
dc.contributor.author전태주-
dc.contributor.author황성호-
dc.date.accessioned2014-12-18T08:57:53Z-
dc.date.available2014-12-18T08:57:53Z-
dc.date.issued2013-
dc.identifier.issn0938-7994-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/87280-
dc.description.abstractOBJECTIVES: To compare tumour enhancement patterns measured using dynamic contrast-enhanced (DCE)-CT with tumour metabolism measured using positron emission tomography (PET)-CT in patients with non-small cell lung cancer (NSCLC) and stable disease after chemotherapy or chemoradiotherapy. METHODS: After treatment, 75 NSCLC tumours in 65 patients who had stable disease on DCE-CT according to Response Evaluation Criteria in Solid Tumour (RECIST) were evaluated using PET-CT. On DCE-CT, relative enhancement ratios (RER) of tumour at 30, 60, 90, 120 s and 5 min after injection of contrast material were measured. Metabolic responses of tumours were classified into two groups according to the maximum standardized uptake value (SUVmax) by PET-CT: complete metabolic response (CR) with an SUVmax of less than 2.5, and noncomplete metabolic response (NR) with an SUVmax of at least 2.5. RESULTS: Using the optimal RER₆₀ cutoff value of 43.7 % to predict NR of tumour gave 95.7 % sensitivity, 64.2 % specificity, and 82.1 % positive and 95.0 % negative predictive values. After adjusting for tumour size, the odds ratio for NR in tumour with an RER60 of at least 43.7 % was 70.85 (95 % CI = 7.95-630.91; P < 0.05). CONCLUSIONS: Even when disease was stable according to RECIST, DCE-CT predicted hypermetabolic status of residual tumour in patients with NSCLC after treatment. KEY POINTS : • Dynamic contrast-enhanced CT (DCE-CT) can provide useful metabolic information about non-small cell lung cancer. • NSCLC lesions, even grossly stable after treatment, show various metabolic states. • DCE-CT enhancement patterns correlate with tumour metabolic status as shown by PET. • DCE-CT helps to assess hypermetabolic NSCLC as stable disease after treatment.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfEUROPEAN RADIOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHArea Under Curve-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/diagnosis*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/diagnostic imaging*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/therapy-
dc.subject.MESHChemoradiotherapy/methods-
dc.subject.MESHContrast Media/pharmacology*-
dc.subject.MESHDrug Therapy/methods-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18/pharmacology-
dc.subject.MESHHumans-
dc.subject.MESHImage Processing, Computer-Assisted-
dc.subject.MESHLung Neoplasms/diagnosis*-
dc.subject.MESHLung Neoplasms/diagnostic imaging*-
dc.subject.MESHLung Neoplasms/therapy-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOdds Ratio-
dc.subject.MESHPositron-Emission Tomography/methods-
dc.subject.MESHProspective Studies-
dc.subject.MESHSensitivity and Specificity-
dc.subject.MESHTime Factors-
dc.subject.MESHTomography, X-Ray Computed/methods*-
dc.subject.MESHTreatment Outcome-
dc.titleDynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiology (영상의학)-
dc.contributor.googleauthorSung Ho Hwang-
dc.contributor.googleauthorMi Ri Yoo-
dc.contributor.googleauthorChul Hwan Park-
dc.contributor.googleauthorTae Joo Jeon-
dc.contributor.googleauthorSang Jin Kim-
dc.contributor.googleauthorTae Hoon Kim-
dc.identifier.doi10.1007/s00330-012-2755-0-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03557-
dc.contributor.localIdA01086-
dc.contributor.localIdA00528-
dc.contributor.localIdA01722-
dc.contributor.localIdA04467-
dc.relation.journalcodeJ00851-
dc.identifier.eissn1432-1084-
dc.identifier.pmid23300040-
dc.identifier.urlhttp://link.springer.com/article/10.1007/s00330-012-2755-0-
dc.subject.keywordNon-small cell lung cancer-
dc.subject.keywordComputed tomography-
dc.subject.keyword18F-fluoro-deoxyglucose positron emission tomography-
dc.subject.keywordEnhancement pattern-
dc.subject.keywordStandardized uptake value-
dc.contributor.alternativeNameKim, Sang Jin-
dc.contributor.alternativeNameKim, Tae Hoon-
dc.contributor.alternativeNamePark, Chul Hwan-
dc.contributor.alternativeNameJeon, Tae Joo-
dc.contributor.alternativeNameHwang, Sung Ho-
dc.contributor.affiliatedAuthorJeon, Tae Joo-
dc.contributor.affiliatedAuthorKim, Tae Hoon-
dc.contributor.affiliatedAuthorKim, Sang Jin-
dc.contributor.affiliatedAuthorPark, Chul Hwan-
dc.contributor.affiliatedAuthorHwang, Sung Ho-
dc.rights.accessRightsnot free-
dc.citation.volume23-
dc.citation.number6-
dc.citation.startPage1573-
dc.citation.endPage1581-
dc.identifier.bibliographicCitationEUROPEAN RADIOLOGY, Vol.23(6) : 1573-1581, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.